Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Chief Executive Officer Lyn Baranowski said the company completed its IPO just over a month ago and was participating in its first investor conference as a public company. Avalyn is focused on pulmonary fibrosis, a disease Baranowski described as a “deadly diagnosis” with typical survival of three to five years and survival rates “worse than most forms of cancer.”
